Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition.

Bischoff H, Angerbauer R, Boberg M, Petzinna D, Schmidt D, Steinke W, Thomas G.

Atherosclerosis. 1998 Sep;139 Suppl 1:S7-13. Review.

PMID:
9811153
2.

Biotransformation of cerivastatin in mice, rats, and dogs in vivo.

Boberg M, Angerbauer R, Kanhai WK, Karl W, Kern A, Radtke M, Steinke W.

Drug Metab Dispos. 1998 Jul;26(7):640-52.

PMID:
9660846
3.

Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor.

Bischoff H, Angerbauer R, Bender J, Bischoff E, Faggiotto A, Petzinna D, Pfitzner J, Porter MC, Schmidt D, Thomas G.

Atherosclerosis. 1997 Nov;135(1):119-30.

PMID:
9395280
4.

Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved.

Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M.

Drug Metab Dispos. 1997 Mar;25(3):321-31.

PMID:
9172950

Supplemental Content

Loading ...
Support Center